NIR Fluorescence Imaging of Lymphatic Transport Using ICG

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this phase 1 study, the lymphatic transport will be examined using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities in healthy individuals using a MultiSpectral Imaging System (MSImager).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Rochester
• Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institutes of Health (NIH)

Criteria

Inclusion Criteria:

• Ability to provide written informed consent

• Subjects can be either gender but must be at least 18 years old.

• Rheumatoid arthritis subjects may fulfill 2010 American College of Rheumatology criteria.

• Active rheumatoid arthritis subjects, with at least 2 tender or swollen joints.

• Subjects participating in the clearance arm of the study must not have ICG injections for at least 10 weeks.

Exclusion Criteria:

• Individuals with active systemic disorders or inflammatory conditions other than rheumatoid arthritis, (such as chronic infections with hepatitis B, hepatitis C or HIV) that would confound the study results.

• Known sensitivity to iodine because of residual iodide in Indocyanine Green

• Pregnant women should not participate.